RC
RBC Capital Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
626
Surgery Partners
SGRY
$2.83B
|
BH
Ben Hendrix
| $22.08 | $35 |
59%
upside
| Outperform |
25 Mar ‘25
5 months ago |
|
627
NCR Voyix
VYX
$1.79B
|
DP
Daniel Perlin
| $12.96 | $17 |
31%
upside
| Outperform |
25 Mar ‘25
5 months ago |
|
628
Lexeo Therapeutics
LXEO
$278M
|
LI
Luca Issi
| $5.14 | $20 |
289%
upside
| Outperform |
25 Mar ‘25
5 months ago |
|
629
KB Home
KBH
$4.48B
|
MD
Mike Dahl
| $65.89 | $63 |
4%
downside
| Sector Perform |
25 Mar ‘25
5 months ago |
|
630
Energy Transfer Partners
ET
$59.2B
|
ES
Elvira Scotto
| $17.25 | $23 |
33%
upside
| Outperform |
25 Mar ‘25
5 months ago |
|
631
Brookfield Infrastructure Partners
BIP
$14.3B
|
MC
Maurice Choy
| $30.79 | $40 |
30%
upside
| Outperform |
25 Mar ‘25
5 months ago |
|
632
Liberty Energy
LBRT
$1.65B
|
KM
Keith Mackey
| $10.21 | $19 |
86%
upside
| Sector Perform |
24 Mar ‘25
5 months ago |
|
633
Prestige Consumer Healthcare
PBH
$3.23B
|
RC
Ryland Conrad
| $65.70 | $97 |
48%
upside
| Sector Perform |
21 Mar ‘25
5 months ago |
|
634
Verastem
VSTM
$634M
|
GR
Gregory Renza
| $10.30 | $14 |
36%
upside
| Outperform |
21 Mar ‘25
5 months ago |
|
635
Alnylam Pharmaceuticals
ALNY
$62.8B
|
LI
Luca Issi
| $479.13 | $330 |
31%
downside
| Outperform |
21 Mar ‘25
5 months ago |
|
636
Accenture
ACN
$157B
|
DP
Daniel Perlin
| $251.95 | $392 |
56%
upside
| Outperform |
21 Mar ‘25
5 months ago |
|
637
Twilio
TWLO
$16.5B
|
RJ
Rishi Jaluria
| $107.33 | $75 |
30%
downside
| Underperform |
19 Mar ‘25
5 months ago |
|
638
Pyxis Oncology
PYXS
$115M
|
LT
Leonid Timashev
| $1.85 | $8 |
332%
upside
| Outperform |
19 Mar ‘25
5 months ago |
|
639
Korro Bio
KRRO
$333M
|
LI
Luca Issi
| $35.51 | $95 |
168%
upside
| Outperform |
19 Mar ‘25
5 months ago |
|
640
Sangamo Therapeutics
SGMO
$159M
|
LI
Luca Issi
| $0.5266 | $2 |
280%
upside
| Sector Perform |
18 Mar ‘25
5 months ago |
|
641
GE Vernova
GEV
$164B
|
CD
Christopher Dendrinos
| $602.59 | $445 |
26%
downside
| Outperform |
18 Mar ‘25
5 months ago |
|
642
Sibanye-Stillwater
SBSW
$6.05B
|
MC
Marina Calero
| $8.55 | $5.30 |
38%
downside
| Outperform |
18 Mar ‘25
5 months ago |
|
643
Ocular Therapeutix
OCUL
$2.23B
|
LI
Luca Issi
| $12.82 | $17 |
33%
upside
| Outperform |
18 Mar ‘25
5 months ago |
|
644
Bank of New York Mellon
BK
$74.8B
|
GC
Gerard Cassidy
| $106.03 | $90 |
15%
downside
| Sector Perform |
17 Mar ‘25
5 months ago |
|
645
O-I Glass
OI
$1.97B
|
AV
Arun Viswanathan
| $12.81 | $16 |
25%
upside
| Outperform |
17 Mar ‘25
5 months ago |
|
646
MeiraGTx Holdings
MGTX
$617M
|
LI
Luca Issi
| $7.67 | $13 |
69%
upside
| Outperform |
17 Mar ‘25
5 months ago |
|
647
MPLX
MPLX
$51.2B
|
ES
Elvira Scotto
| $50.21 | $58 |
16%
upside
| Outperform |
17 Mar ‘25
5 months ago |
|
648
Nextracker
NXT
$9.69B
|
CD
Christopher Dendrinos
| $65.46 | $55 |
16%
downside
| Outperform |
17 Mar ‘25
5 months ago |
|
649
Array Technologies
ARRY
$1.25B
|
CD
Christopher Dendrinos
| $8.18 | $7 |
14%
downside
| Sector Perform |
17 Mar ‘25
5 months ago |
|
650
EverCommerce
EVCM
$2.1B
|
MH
Matthew Hedberg
| $11.57 | $11 |
5%
downside
| Outperform |
14 Mar ‘25
5 months ago |
|